奈达铂联合吉西他滨治疗晚期非小细胞肺癌临床研究

目的观察奈达铂联合吉西他滨治疗晚期非小细胞肺癌疗效及不良反应。方法选择经病理组织学或细胞形态学检查确诊为非小细胞肺癌的患者22例,所有入组病例均采用奈达铂80～100mg/m2静脉注射,第1天,吉西他滨800mg/m2静脉注射,第1、8天,每21天重复用药,连用两个周期后,评价疗效。同时给予托烷司琼5mg,静脉注射,每天1次,对症止吐。结果本组病例疗效评价,其中CR0例,PR8例,NC6例,PD8例,RR（PR＋CR）为36.4%（8/22）,不良反应主要表现为轻度恶心呕吐,无Ⅲ～Ⅳ度恶心呕吐发生,骨髓抑制轻,Ⅰ～Ⅱ度骨髓抑制16例,Ⅲ度骨髓抑制2例,无Ⅳ度骨髓抑制发生。结论吉西他滨联合奈达铂治疗晚期肺癌有较好的疗效,并且毒性反应可以控制,值得临床推广使用。

Nedaplatin combined gemcitabine treatment of advanced non-small cell lung cancer

Objective To observe nedaplatin combined gemcitabine treatment of advanced non-small cell lung cancer and adverse reactions.Methods The pathology or cell morphology to confirm the diagnosis in patients with non-small cell lung cancer,22 cases were all into the group of patients using intravenous nedaplatin 80～100mg/m2 day 1,gemcitabine（Gem）800mg/m2 IV,day1,8.21days to repeat the treatment,used evaluated after two cycles.While giving Tropisetron 5mg,intravenous injection,day 1,8.Results Clinical evaluation of patients,including CR 0 case,PR 8 cases,NC 6 cases,PD 8 cases,RR（PR＋CR）（8/22）36.4%,mainly mild adverse reaction of nausea and vomiting,no Ⅲ～Ⅳ degree of nausea and vomiting,Ⅰ～Ⅱmild bone marrow suppression 16 cases,Ⅲmyelosuppression 2 cases,no Ⅳ myelosuppression.Conclusion Gemcitabine combined with nedaplatin treatment of advanced lung cancer has better exact effect,and toxicity can be controlled,is worthy of clinical use.